Analogs of somatostatin (SRIF) such as octreotide exert antiproliferative effects that are mediated directly by tumoral SRIF receptors or indirectly by downmodulation of factors that stimulate tumor growth. Direct and indirect antiproliferative effects have been demonstrated in certain SRIF receptor-positive and -negative human breast cancer models in nude mice, respectively. These antiproliferative mechanisms are also being explored in other cancer types including pancreatic cancer. While clinical pilot studies have indicated that a fraction of pancreatic adenocarcinomas respond to high-dose octreotide treatment, it is known from receptor autoradiographic and scintigraphic studies that human pancreatic carcinomas fail to express SRIF receptors, in contrast to rat pancreatic carcinomas or human endocrine pancreatic cancer. Studies on the potential anticancer effect of octreotide on the growth of experimental human pancreatic cancer and its SRIF receptor status have been controversial. Therefore, we investigated in vivo the effects of octreotide on the growth of MIA PaCa-2 human pancreatic carcinomas raised from cultured cells with a low passage number after receipt from the American Type Culture Collection. Nude mice bearing MIA PaCa-2 tumors were treated with a single injection of the recently developed octreotide long-acting release formulation, "SMS pa LAR." This treatment was well tolerated and resulted in a highly significant inhibition of tumor growth during weeks three and eight after administration. MIA PaCa-2 tumors were removed after eight weeks and processed for RT-PCR analysis using probes specific for each of the five somatostatin receptor subtypes sstrsst5. This analysis revealed that MIA PaCa-2 tumors, like human pancreatic adenocarcinomas, do not express any of the five SRIF receptor subtypes, suggesting an indirect mode of tumor growth inhibition. In summary, the depot formulation SMS pa LAR exerted long-lasting antiproliferative effects in SRIF receptor-negative human pancreatic carcinomas in nude mice.
INTRODUCTION
The concept of direct and indirect cell growth inihibition by somatostatin (SRIF)b and peptide analogs such as octreotide is used to explain their antiproliferative action in SRIF receptor-positive and negative tumors [1, 2] (Figure 1 ). The direct effect implies that octreotide binds to SRIF receptors on tumor cells leading to activation of a phosphotyrosine phosphatase (PTPase) and abrogation of cell growth that is induced via growth factor-regulated tyrosine kinases (TK) (Figure 1) . Buscail et By contrast, support for the indirect mechanism is less clearcut, partially because it can be studied only in vivo. The indirect mechanism is apparently operative through downregulation of tumor growth stimuli including IGF-1, EGF or GH [5, 6] (Figure 1 ). An indirect effect may occur in cancer cells both with and without SRIF receptors. Based on the concept of the indirect effect SRIF analogs have been investigated as treatment for SRIF receptor-negative cancers including pancreatic cancer. However, models for the study of the indirect antitumor effects are rare. Controversial results were obtained in various laboratories with the MIA PaCa-2 human pancreatic carcinoma model. Gillespie et al. [7] could neither detect SRIF receptors nor an effect of RC-160 on the growth of MIA PaCa-2 cells in vitro. This suggested to us that MIA PaCa-2 tumors, provided that they were sensitive to octreotide in the nude mouse, would be a candidate model to study the indirect mechanism. By contrast, Radulovic et al. [8] demonstrated that this cell line was growth inhibited by RC-160 and also expressed binding sites for radiolabeled RC- formed essentially as described previously [10] except for the primer pairs for the sst1 and sst4 receptor specific RT-PCRs. For sst1, we used the primers RS180 (5'-TCA GCT GGG ATG TTC CCC AAT G-3') and RS190 (5'-GTC GTC TTG CTC GGC GAA CAC G-3'), and for sst4 the primers HS48 (5'-ACC AAC ATC TAC CTG CTC AAC CTG G-3') and HS49 (5'-GCA TAG TAG TCC AGG GGC TC-3') were used.
RESULTS AND DISCUSSION Nude mice bearing MIA PaCa-2 tumors were treated either with placebo or a single injection of the recently developed octreotide long-acting release formulation SMS pa LAR (Figure 2 ). The treatment with SMS pa LAR resulted in a highly significant (p < .0002) inhibition of tumor growth for the observation period of weeks three to eight. The mean volume of treated tumors was 25.8 percent of control at the end of the experiment. Since the body weight of octreotide-treated mice did not show the distinct drop that is usually observed with most cytotoxic anticancers, the depot formulation is apparently well tolerated (Table 1 The SRIF receptor status of 12 individual MIA PaCa-2 tumors was determined at the end of the eight-week experiment. Tumors were excised and processed for RT-PCR analysis using probes specific for each of the five somatostatin receptor subtypes sstl-sst5 (Figure 3 ). This analysis revealed that these MIA PaCa-2 tumors, under the experimental conditions described, failed to express detectable levels of any of the five somatostatin receptor subtypes except for two tumors that gave very weak RT-PCR signals for the sst3 mRNA. It should be noted that for sst2, the only human SRIF receptor with high affinity for octreotide, all tumors analyzed were negative in the sensitive human (and in addition mouse) specific RT-PCR assay. Reaction conditions were controlled by including negative and positive (human sst2 cDNA) controls (Figure 3) . Interestingly, there was no difference in the findings when the control tumors were compared with the SMS pa LAR-treated tumors (Figure 3) . The same negative results were obtained by analyzing MIA PaCa-2 cells in vitro (data not shown). Thus, the MIA PaCa-2 model is apparently identical in this aspect to human pancreatic adenocarcinomas which are SRIF receptor-negative too. Figure 2 [12] showed that veins surrounding human cancer express high levels of somatostatin receptors. Since Tyr3-octreotide was bound with high affinity, the tumor-associated veins probably express sst2 and/or sst5. Danesi et al. [13] demonstrated the antiangiogenic properties of octreotide in various angiogenesis models in vivo such as the rat cornea model and the rat mesentery model.
An important factor for achieving antiproliferative effects is to maintain high octreotide plasma levels for extended time periods. In a separate experiment performed under identical conditions in the AR42J pancreatic tumor nude mouse model, the mean plasma concentration (±SE) of octreotide three weeks after a single injection of SMS pa LAR was 9.3 ± 1.6 nM. This treatment was associated with a potent inhibition of AR42J tumor growth (data not shown). Plasma levels in this range were also shown previoulsy to exert long-lasting antiproliferative effects in the ZR-75-1 mammary tumor bearing nude mouse [9] .
Upp et al. [14] demonstrated that the growth of SKI human pancreatic adenocarcinomas in nude mice is inhibited by octreotide treatment. However, the SRIF receptor status of SKI tumors used in this investigation has not been reported. A very recent study by Fisher et al. [15] also showed that MIA PaCa-2 tumors in nude mice were inhibited by continuous administration of octreotide, while the other pancreatic tumor models tested were unresponsive. In contrast to our study, these MIA PaCa-2 tumors did express SRIF receptors (sst2). Moreover, in a pilot clinical trial, high-dose therapy with octreotide was associated with a tumor response in a fraction of the treated patients [16] . The still limited amount of preclinical and clinical data suggest that certain pancreatic adenocarcinomas respond to SRIF analog treatment. Due to the absence of detectable SRIF receptors in human pancreatic cancer, the underlying antiproliferative effect is expected to be indirect. In summary, a single injection of the depot formulation of SMS pa LAR was well tolerated and exerted long-lasting antiproliferative effects in SRIF receptor-negative human pancreatic carcinomas in nude mice.
